M&A trends in diagnostics and life sciences tools
The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.
Newsletters and Deep Dive digital magazine
The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.
Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs
Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?
Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks